Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Receivables (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Change in Receivables for 2 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 93.75% to $10.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.9 million, a 7.33% decrease, with the full-year FY2025 number at $12.9 million, down 7.33% from a year prior.
  • Change in Receivables was $10.0 million for Q4 2025 at Day One Biopharmaceuticals, up from -$3.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $10.0 million in Q4 2025 to a low of -$3.0 million in Q3 2025.